India’s Sun Pharmaceutical Industries has agreed to acquire the US dermatology company Dusa Pharmaceuticals in a deal valued at approximately US$230 M. With the acquisition, Sun Pharma will gain access to Dusa’s US FDA approved Levulan® (aminolevulinic acid hydrochloride) photodynamic therapy platform for actinic keratoses and the BLU-U® blue light photodynamic therapy illuminator for acne. The company is looking to increase its footprint in the US dermatology market, major players in which include Valeant Pharmaceuticals, Novartis’ Sandoz unit and GlaxoSmithKline.